Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Avatrombopag
Drug ID BADD_D02497
Description Avatrombopag (_Doptelet_), is an orally administered, small-molecule thrombopoietin receptor (c-Mpl) agonist which increases platelet number, but not platelet activation [A33097], [L2824]. This decreases the need for blood transfusions [L2824]. Patients with thrombocytopenia and chronic liver disease (leading to thrombocytopenia) often require platelet transfusions before surgical procedures to decrease the risk of bleeding [A33095]. Thrombocytopenia (or decreased numbers of platelets) is a common complication in patients suffering from chronic liver disease, either as an immediate result of liver disease or a consequence of interferon-based antiviral therapy [F95]. Avatrombopag was approved by the FDA on May 21, 2018 for thrombocytopenia (low platelets) in adults with chronic liver disease who are scheduled to undergo a procedure [L2931]. It is administered orally as _avatrombopag maleate_, its salt form [L2927]. _Doptelet_ (Avatrombopag) is the first orally administered treatment option for patients with chronic liver disease, allowing a large population of patients to avoid a platelet transfusion before a procedure by increasing platelet counts to the optimal level of greater or equal to 50,000 per microliter [L2932].
Indications and Usage Indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure [FDA label].
Marketing Status Not Available
ATC Code B02BX08
DrugBank ID DB11995
KEGG ID D10306
MeSH ID C533238
PubChem ID 9852519
TTD Drug ID D0W1DI
NDC Product Code Not Available
Synonyms avatrombopag | Doptelet | AKR 501 | AKR501 | AKR-501 | YM 477 | YM477 | YM-477 | E5501 compound | 1-(3-chloro-5-((4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl)carbamoyl)-2-pyridyl)piperidine-4-carboxylic acid
Chemical Information
Molecular Formula C29H34Cl2N6O3S2
CAS Registry Number 570406-98-3
SMILES C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=C S6)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.001089%Not Available
Abdominal pain07.01.05.0020.001634%
Anaemia01.03.02.0010.001089%
Arthralgia15.01.02.0010.001089%
Asthenia08.01.01.0010.003267%Not Available
Back pain15.03.04.0050.001634%
Bone pain15.02.01.0010.001089%
Constipation07.02.02.0010.001089%
Death08.04.01.001--
Diarrhoea07.02.01.0010.001634%
Dizziness02.01.02.004; 24.06.02.007; 17.02.05.0030.002723%
Epistaxis24.07.01.005; 22.04.03.0010.001089%
Fatigue08.01.01.0020.006534%
Feeling abnormal08.01.09.0140.001089%Not Available
Haemoglobin decreased13.01.05.0030.001089%Not Available
Headache17.14.01.0010.011980%
Hepatic encephalopathy17.13.01.003; 09.01.03.0060.001089%Not Available
Insomnia19.02.01.002; 17.15.03.0020.001089%
Loss of consciousness17.02.04.0040.001089%Not Available
Malaise08.01.01.0030.001634%
Myocardial infarction24.04.04.009; 02.02.02.0070.000284%
Nausea07.01.07.0010.005445%
Pain08.01.08.0040.001089%
Pain in extremity15.03.04.0100.001089%
Platelet count decreased13.01.04.0010.003812%
Pneumonia22.07.01.003; 11.01.09.0030.001089%Not Available
Pyrexia08.05.02.0030.001634%
Somnolence19.02.05.003; 17.02.04.0060.001089%
Swelling08.01.03.0150.001089%Not Available
Vomiting07.01.07.0030.003267%
The 1th Page    1    Total 1 Pages